CADTH Canadian Drug Expert Committee recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication: in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF) and urgent HF visit

The CADTH Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin (Forxiga) should be reimbursed as an adjunct to standard of care therapy, for the treatment of HFrEF only if certain conditions are met

Bibliographic Details

Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2021, January 6, 2021
Edition:	Version 1.0
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK572048
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa